RNAZ·89357L501·US·equity·Healthcare - Biotechnology-Activist
RNAZ (TRANSCODE THERAPEUTICS INC) is held by 4 institutional investors as of Q4 2025. Net institutional sentiment: Mixed.
See how RNAZ's score breaks down across 4 SEC sources
This is taking longer than usual. Please try again in a moment.
Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer